Application of apolipoprotein ApoA1 in detection of drug resistance of cervical cancer to platinum chemotherapy

A technology for apolipoprotein and cervical cancer, which is applied in the field of medicine and can solve problems such as unclear mechanisms

Pending Publication Date: 2021-06-29
BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no predictive target and therapeutic target for cervical cancer drug resistance, and th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of apolipoprotein ApoA1 in detection of drug resistance of cervical cancer to platinum chemotherapy
  • Application of apolipoprotein ApoA1 in detection of drug resistance of cervical cancer to platinum chemotherapy
  • Application of apolipoprotein ApoA1 in detection of drug resistance of cervical cancer to platinum chemotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Screening of platinum-based chemotherapy resistance differential proteins in cervical squamous cell carcinoma cells:

[0024] Cervical squamous cell carcinoma SiHa cells were cultured in platinum-based chemotherapy drugs for 14 days. The SiHa cell line resistant to platinum-based chemotherapy was cultivated, and proteins were extracted. The total number of proteins identified by iTRAQ reagent labeling combined with LC-MS / MS was 7139, and the low Molecular weight range (1000-50000Da) biomarker screening results, through the comparative analysis of differentially expressed proteins in the carboplatin group and the MOCK group, in order to express the protein in the tissue sample that was up-regulated by more than 1.2 times or down-regulated by less than 0.83 times (p<0.05) As a screening standard, combined with literature search related protein functions, 96 identifiable differential protein peaks were screened. Through GO classification and KEGG annotation, 85 proteins wi...

Embodiment 2

[0029] Overexpression of ApoA1 platinum chemotherapy resistance protein verification:

[0030] According to the literature at home and abroad, as well as the results of GO and KEGG analysis, the up-regulated expression of ApoA1 was selected as the target protein for gene overexpression. A lentivirus overexpressing ApoA1 (without fluorescence) was constructed and co-cultured with SiHa cells. Real-PCR was used to detect the expression of overexpressed ApoA1 in SiHa cells, and it was found that the expression abundance of ApoA1 gene in the overexpression group (Overexpression, OE) group was 355.459 times that of the NC group. CCK-8 was used to detect the effect of ApoA1 overexpression on the concentration of chemotherapeutic drug (carboplatin). After the carboplatin group overexpressed ApoA1, the corresponding concentration of IC50 was 86.31ug / ml, which was higher than that of the NC group, and the corresponding drug concentration of IC50 was 51.88ug / ml (such as Figure 1-2 sho...

Embodiment 3

[0032] Expression of ApoA1 in cervical cancer drug-resistant tissues:

[0033] Obtained 10 cases of tumor tissue from patients with locally advanced cervical squamous cell carcinoma. All patients received NACT treatment of CBP combined with paclitaxel before the first operation. The time standard was 21-28 days after the end of chemotherapy treatment, according to WHO solid tumor efficacy evaluation criteria (Response evaluation criteria in solid tumors, RECIST) standard to evaluate the effect of chemotherapy, patients were divided into complete response (Complete response, CR), partial response (Partial remission, PR), stable disease (Stable disease, SD), disease progression ( Progressive disease, PD), where SD+PD is the chemotherapy-resistant group, and CR is the chemotherapy-sensitive group, with 5 specimens in each group. The expression of ApoA1 protein was determined by IHC. The results showed that ApoA1 was highly expressed in 40% (2 / 5) of squamous cell carcinoma tissue...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of apolipoprotein ApoA1 in detection of drug resistance of cervical cancer to platinum chemotherapy, and the research of the invention defines that the apolipoprotein ApoA1 can be used as a cervical cancer platinum chemotherapy drug resistance marker, and regulates and controls an MAPK signal channel through STAT1 to promote cell proliferation so as to cause the chemotherapy resistance of platinum drugs.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of apolipoprotein ApoA1 in the detection of cervical cancer drug resistance to platinum chemotherapy. Background technique [0002] Cervical cancer is the fourth most common malignant tumor that threatens women's health worldwide. According to statistics in 2012, there are 528,000 new cases of cervical cancer and 266,000 new deaths each year in the world. my country is the country with the largest number of new cases and deaths. It can be seen that cervical cancer seriously threatens women's lives. Although the HPV vaccine has recently been launched in my country, it is only suitable for a small number of specific groups of people, and the HPV vaccine cannot prevent all types of high-risk HPV infection, which means that it cannot completely block the occurrence of cervical cancer; Screening system enables early detection and early treatment. However, based on my...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574G01N33/68
CPCG01N33/57411G01N33/57484G01N33/68G01N2333/775
Inventor 何玥吴玉梅
Owner BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap